Literature DB >> 6437053

Protective immunity against clinical sarcocystosis in cattle.

R Fayer, J P Dubey.   

Abstract

Five experiments involving 50 calves (Bos taurus) were conducted to determine if oral infection with sporocysts of the pathogen Sarcocystis cruzi or the non-pathogen Sarcocystis hirsuta would stimulate development of a protective immunity against illness or death from challenge infection with large numbers of S. cruzi sporocysts. Four experiments involved Holstein calves housed in individual pens in isolation buildings; one experiment involved Hereford calves on an open range. Calves infected with 50 000 to 100 000 S. cruzi sporocysts were protected from illness and death that would have resulted from challenge infections with 250 000 or 500 000 S. cruzi sporocysts given 70-252 days later. Calves treated with the anticoccidial drug amprolium from 21 to 35 days after being given an immunizing infection with S. cruzi to reduce clinical signs of the immunizing infection were also protected. Non-immunized calves and those given S. hirsuta sporocysts were not protected.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437053     DOI: 10.1016/0304-4017(84)90071-2

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  3 in total

1.  Ultrastructural and transmission evidence of Sarcocystis cruzi associated with eosinophilic myositis in cattle.

Authors:  A A Gajadhar; W C Marquardt
Journal:  Can J Vet Res       Date:  1992-01       Impact factor: 1.310

2.  Evidence that antibodies against recombinant SnSAG1 of Sarcocystis neurona merozoites are involved in infection and immunity in equine protozoal myeloencephalitis.

Authors:  Siobhan Ellison; Sharon Witonsky
Journal:  Can J Vet Res       Date:  2009-07       Impact factor: 1.310

Review 3.  Sarcocystosis in South American camelids: The state of play revisited.

Authors:  Muhammad A Saeed; Mohammed H Rashid; Jane Vaughan; Abdul Jabbar
Journal:  Parasit Vectors       Date:  2018-03-06       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.